210 related articles for article (PubMed ID: 36459496)
21. 2-Deoxyglucose Suppresses ERK Phosphorylation in LKB1 and Ras Wild-Type Non-Small Cell Lung Cancer Cells.
Sun L; Liu X; Fu H; Zhou W; Zhong D
PLoS One; 2016; 11(12):e0168793. PubMed ID: 28033353
[TBL] [Abstract][Full Text] [Related]
22. Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer.
Osude C; Lin L; Patel M; Eckburg A; Berei J; Kuckovic A; Dube N; Rastogi A; Gautam S; Smith TJ; Sreenivassappa SB; Puri N
Cells; 2022 May; 11(10):. PubMed ID: 35626731
[TBL] [Abstract][Full Text] [Related]
23. Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Howe GA; Xiao B; Zhao H; Al-Zahrani KN; Hasim MS; Villeneuve J; Sekhon HS; Goss GD; Sabourin LA; Dimitroulakos J; Addison CL
PLoS One; 2016; 11(3):e0150567. PubMed ID: 26962872
[TBL] [Abstract][Full Text] [Related]
24. Concurrent regulation of LKB1 and CaMKK2 in the activation of AMPK in castrate-resistant prostate cancer by a well-defined polyherbal mixture with anticancer properties.
MacDonald AF; Bettaieb A; Donohoe DR; Alani DS; Han A; Zhao Y; Whelan J
BMC Complement Altern Med; 2018 Jun; 18(1):188. PubMed ID: 29914450
[TBL] [Abstract][Full Text] [Related]
25. Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells.
Xie Z; Dong Y; Scholz R; Neumann D; Zou MH
Circulation; 2008 Feb; 117(7):952-62. PubMed ID: 18250273
[TBL] [Abstract][Full Text] [Related]
26. Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer.
Wang Y; Li N; Jiang W; Deng W; Ye R; Xu C; Qiao Y; Sharma A; Zhang M; Hung MC; Lin SH
Clin Cancer Res; 2018 Nov; 24(22):5744-5756. PubMed ID: 30068711
[No Abstract] [Full Text] [Related]
27. Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer.
Carretero J; Medina PP; Blanco R; Smit L; Tang M; Roncador G; Maestre L; Conde E; Lopez-Rios F; Clevers HC; Sanchez-Cespedes M
Oncogene; 2007 Mar; 26(11):1616-25. PubMed ID: 16953221
[TBL] [Abstract][Full Text] [Related]
28. LKB1 Loss induces characteristic patterns of gene expression in human tumors associated with NRF2 activation and attenuation of PI3K-AKT.
Kaufman JM; Amann JM; Park K; Arasada RR; Li H; Shyr Y; Carbone DP
J Thorac Oncol; 2014 Jun; 9(6):794-804. PubMed ID: 24828662
[TBL] [Abstract][Full Text] [Related]
29. PARP Inhibition Induces Synthetic Lethality and Adaptive Immunity in LKB1-Mutant Lung Cancer.
Long LL; Ma SC; Guo ZQ; Zhang YP; Fan Z; Liu LJ; Liu L; Han DD; Leng MX; Wang J; Guo XJ; Tan JL; Cai XT; Lin Y; Pan X; Wu DH; Bai X; Dong ZY
Cancer Res; 2023 Feb; 83(4):568-581. PubMed ID: 36512628
[TBL] [Abstract][Full Text] [Related]
30. The CREB coactivator CRTC2 promotes oncogenesis in LKB1-mutant non-small cell lung cancer.
Rodón L; Svensson RU; Wiater E; Chun MGH; Tsai WW; Eichner LJ; Shaw RJ; Montminy M
Sci Adv; 2019 Jul; 5(7):eaaw6455. PubMed ID: 31355336
[TBL] [Abstract][Full Text] [Related]
31. AMPK Causes Cell Cycle Arrest in LKB1-Deficient Cells via Activation of CAMKK2.
Fogarty S; Ross FA; Vara Ciruelos D; Gray A; Gowans GJ; Hardie DG
Mol Cancer Res; 2016 Aug; 14(8):683-95. PubMed ID: 27141100
[TBL] [Abstract][Full Text] [Related]
32. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
Cascone T; Xu L; Lin HY; Liu W; Tran HT; Liu Y; Howells K; Haddad V; Hanrahan E; Nilsson MB; Cortez MA; Giri U; Kadara H; Saigal B; Park YY; Peng W; Lee JS; Ryan AJ; Jüergensmeier JM; Herbst RS; Wang J; Langley RR; Wistuba II; Lee JJ; Heymach JV
Clin Cancer Res; 2017 Sep; 23(18):5489-5501. PubMed ID: 28559461
[No Abstract] [Full Text] [Related]
33. LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition.
Mahoney CL; Choudhury B; Davies H; Edkins S; Greenman C; Haaften Gv; Mironenko T; Santarius T; Stevens C; Stratton MR; Futreal PA
Br J Cancer; 2009 Jan; 100(2):370-5. PubMed ID: 19165201
[TBL] [Abstract][Full Text] [Related]
34. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
35. Inactivation of AMPK Leads to Attenuation of Antigen Presentation and Immune Evasion in Lung Adenocarcinoma.
Gao Y; Päivinen P; Tripathi S; Domènech-Moreno E; Wong IPL; Vaahtomeri K; Nagaraj AS; Talwelkar SS; Foretz M; Verschuren EW; Viollet B; Yan Y; Mäkelä TP
Clin Cancer Res; 2022 Jan; 28(1):227-237. PubMed ID: 34667030
[TBL] [Abstract][Full Text] [Related]
36. CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells.
Kim J; Hu Z; Cai L; Li K; Choi E; Faubert B; Bezwada D; Rodriguez-Canales J; Villalobos P; Lin YF; Ni M; Huffman KE; Girard L; Byers LA; Unsal-Kacmaz K; Peña CG; Heymach JV; Wauters E; Vansteenkiste J; Castrillon DH; Chen BPC; Wistuba I; Lambrechts D; Xu J; Minna JD; DeBerardinis RJ
Nature; 2017 Jun; 546(7656):168-172. PubMed ID: 28538732
[TBL] [Abstract][Full Text] [Related]
37. Involvement of E-cadherin/AMPK/mTOR axis in LKB1-induced sensitivity of non-small cell lung cancer to gambogic acid.
Li X; Tang X; Su J; Xu G; Zhao L; Qi Q
Biochem Pharmacol; 2019 Nov; 169():113635. PubMed ID: 31513784
[TBL] [Abstract][Full Text] [Related]
38. Activation of protein kinase C zeta by peroxynitrite regulates LKB1-dependent AMP-activated protein kinase in cultured endothelial cells.
Xie Z; Dong Y; Zhang M; Cui MZ; Cohen RA; Riek U; Neumann D; Schlattner U; Zou MH
J Biol Chem; 2006 Mar; 281(10):6366-75. PubMed ID: 16407220
[TBL] [Abstract][Full Text] [Related]
39. Honokiol activates the LKB1-AMPK signaling pathway and attenuates the lipid accumulation in hepatocytes.
Seo MS; Kim JH; Kim HJ; Chang KC; Park SW
Toxicol Appl Pharmacol; 2015 Apr; 284(2):113-24. PubMed ID: 25737164
[TBL] [Abstract][Full Text] [Related]
40. Metformin inhibits growth of human non-small cell lung cancer cells via liver kinase B-1-independent activation of adenosine monophosphate-activated protein kinase.
Guo Q; Liu Z; Jiang L; Liu M; Ma J; Yang C; Han L; Nan K; Liang X
Mol Med Rep; 2016 Mar; 13(3):2590-6. PubMed ID: 26847819
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]